HK Stock Market Move | BAO PHARMA-B (02659) surged more than 6% against the market, breaking through the top and being included in the Hang Seng Composite Index. It is expected that KJ017 will receive NDA approval in the first quarter of 26th year.

BAO PHARMA-B (02659) rose more than 6% against the market trend, reaching a high of 190 Hong Kong dollars during trading, setting a new record high. As of the time of reporting, it has risen by 6.09% to 190 Hong Kong dollars, with a trading volume of 28.0561 million Hong Kong dollars. On the news front, on February 13, Hang Seng Index Company announced the quarterly review results of the Hang Seng Index series as of December 31, 2025. BAO PHARMA-B (02659) has been included in the Hang Seng Composite Index. This change will be implemented after the market closes on March 6, 2026 (Friday) and will take effect on March 9, 2026 (Monday). At that time, the Shanghai and Shenzhen stock exchanges will adjust the scope of eligible investment targets for Hong Kong stocks through Stock Connect. According to LiveReport's big data forecast, Baoji Pharmaceutical is expected to seize this opportunity to be included in the Stock Connect and welcome a new development opportunity. It is reported that Baoji Pharmaceutical has China's first recombinant human hyaluronidase KJ017, used for large-volume subcutaneous drug administration; the world's first IgG degrading enzyme KJ103, which has the "best in class" potential in terms of low pre-storage antibodies and dosing frequency, used for antibody-mediated autoimmune diseases; and a long-acting follicle-stimulating hormone drug SJ02 that has been cooperatively validated for use in reproductive assistance. Western Bull Securities pointed out that in terms of products that are about to be commercialized or are currently being commercialized, Baoji Pharmaceutical has already established a clear commercialization model and timetable. Among them, the recombinant human hyaluronidase KJ017 is not currently sold as a standalone therapy in the Chinese market, and is expected to receive NDA approval in the first quarter of 2026.